Dr. Doug Ethell, Ph.D. is Founder and CEO at Leucadia Therapeutics ( https://www.leucadiatx.com/ ), a pre-clinical-stage company focused on diagnosing, treating and curing Alzheimer's disease. Leucadia's proprietary Arethusta® medical device is designed to restore the flow of cerebrospinal fluid (CSF) through the cribriform plate to flush toxins away from the part of the brain where Alzheimer's disease first appears. The company also recently launched eight Apps that help exercise memory and cognition, including a personalized memory tracker called ProCogny ( www.procogny.com ). ProCogny allows users to play memory-intensive puzzles and games, daily Brain Boost collections of mini-puzzles, and a non-clinical version of the Leucadia Memory Test. Dr. Ethell received a Ph.D. in Neurobiology from The University of British Columbia in Vancouver, was a Human Frontiers of Science Long Term Fellow at The Max Planck Institute for Psychiatry in Munich, a Staff Scientist at The Scripps Research Institute and La Jolla Institute for Allergy & Immunology, and a faculty member at the University of California Riverside. In 2017, Dr. Ethell was Professor of Neuroscience, Chair of Graduate Faculty, and Head of Molecular Neurobiology at The Western Univ of Health Sciences before joining Leucadia Therapeutics full-time. He has published more than 85 peer-reviewed articles and presentation abstracts. In 2020 Dr. Ethell published a novel: "Remembering Apples: A race to cure Alzheimer's disease" ( https://www.amazon.com/Remembering-Apples-race-Alzheimers-disease/dp/1735106607 ).